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ABSTRACT
BackgroundandObjectives:'HVSLWHUDUHO\VHURXVF\VWLFDGHQRPD6&$FDQDVVXPHDSVHXGRVROLGDVSHFWPLPLFNLQJ
RWKHU SDQFUHDWLF QHRSODVPDV QHXURHQGRFULQH WXPRU(86)1$F\WRORJ\KDV ORZGLDJQRVWLF DFFXUDF\GXH WR WKH VFDQW
FHOOXODULW\RIWKHFROOHFWHGVDPSOHV+LVWRORJLFDOGLDJQRVLVLVXVXDOO\PDGHDIWHUUHVHFWLRQ5HFHQWO\HQGFXWWLQJQHHGOHVIRU
(86¿QHQHHGOHELRSV\(86)1%ZKLFKREWDLQWLVVXHFRUHVE\SHQHWUDWLQJWKHOHVLRQVKDYHEHHQGHYHORSHG:HDLPHG
WRDVVHVV WKHFDSDELOLW\RI(86)1%ZLWK6KDUN&RUHQHHGOHV LQ WKHSUHRSHUDWLYHGLDJQRVLVRIVHURXVF\VWLFDGHQRPD
SVHXGRVROLGDSSHDULQJRQLPDJLQJ6D6&$Materials and Methods:%HWZHHQ-DQXDU\DQG-DQXDU\GDWDIURP
FRQVHFXWLYHDGXOWSDWLHQWVZKRZHUHUHIHUUHGIRU(86)1%RIDVROLGSDQFUHDWLFOHVLRQDQGZHUHGLDJQRVHGZLWKKDYLQJ
6&$ZHUHUHWULHYHGIURPDVLQJOHFHQWHULQVWLWXWLRQDOGDWDEDVHResults:7ZRSDWLHQWVZHUHH[FOXGHGEHFDXVHRIPLFURF\VWLF
DVSHFWDW(86+LVWRORJLFDOGLDJQRVLVRI6&$ZDVPDGHE\(86)1%LQWKHUHPDLQLQJSDWLHQWVIHPDOHVPHDQDJHRI
\HDUV/HVLRQVPHDQVL]HRIPPZHUHK\SHUYDVFXODURQFURVVVHFWLRQDOLPDJLQJVOLJKWO\K\SHUGHQVHPDJQHWLF
UHVRQDQFHLPDJLQJZLWK7ZHLJKWHGLPDJHVFDQDQGQHJDWLYHDW*DVRPDWRVWDWLQUHFHSWRUSRVLWURQHPLVVLRQWRPRJUDSK\
DQGÀXRURGHR[\JOXFRVHSRVLWURQHPLVVLRQWRPRJUDSK\(86)1%VDPSOHVZHUHMXGJHGDGHTXDWHIRUDGH¿QLWLYHGLDJQRVLV
LQDOOFDVHVDFKLHYLQJVSHFLPHQVVXLWDEOHIRUKLVWRORJLFDOHYDOXDWLRQDQGVHYHUDODQFLOODU\VWDLQV+LVWRFKHPLFDOSRVLWLYLW\
IRUSHULRGLFDFLG6FKLII3$6DQG3$6ZLWKGLDVWDVHGLJHVWLRQZDVREVHUYHGLQFDVHV,PPXQRKLVWRFKHPLFDOSRVLWLYLW\
IRUDLQKLELQ*/8708&DQGQHJDWLYLW\IRUV\QDSWRSK\VLQDQGFKURPRJUDQLQ$IDYRUHG
6&$GLDJQRVLVConclusions:,QWKHFDVHRISUHRSHUDWLYHZRUNXSVXVSHFWHGIRU6D6&$D³IRUZDUGDFTXLULQJ´QHHGOHFRXOG
LPSURYHWKHUDWHRISUHRSHUDWLYHKLVWRORJLFDOGLDJQRVLV
Key words:(86(86)1$(86ÀQHQHHGOHELRSV\SDQFUHDWLFF\VWVSDQFUHDWLFQHXURHQGRFULQHSDQFUHDWLFVROLGQHRSODVP
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INTRODUCTION
Pancreatic serous cystic neoplasms (SCNs) are benign 
tumors that can be managed conservatively when 
asymptomatic. They represent approximately 1%–2% 
of  all pancreatic tumors,[1] and histologically, they 
consist of  a monostratified epithelium composed of  
cuboidal glycogen-rich cells with round nuclei and 
FODULÀHG F\WRSODVP7KH FOHDU FHOOPRUSKRORJ\ DQG WKH
delicate vascular meshwork composed of  tiny capillaries 
beneath the epithelium are the histological hallmarks 
of  these neoplasms. On surgical specimens, numerous 
macroscopic variants have been described,[2] of  which 
the microcystic type is the most frequently reported 
form (77%). The imaging appearance of  this type 
is honeycomb microcystic with a central scar that is 
VRPHWLPHV FDOFLÀHG7KHVH IHDWXUHV DUHKLJKO\ VXJJHVWLYH
of  serous cystic adenoma (SCA) microcystic type, and 
generally, no further investigations are required to 
confirm the presumptive diagnosis. However, rarely, 
the cysts composing the neoplasm are extremely small 
and crammed each other thus giving the tumor a 
pseudo-solid aspect on imaging (pseudo solid-appearing 
serous cystic adenoma, Sa-SCA). Therefore, as well as 
in less frequent variants such as the SCN macrocystic 
unilocular/oligocystic type,[3] or the rarely described 
solid type,[1-4] there is a differential diagnosis with 
other cystic or solid neoplasms, requiring different 
management from that of  SCN.
At contrast-enhanced cross-sectional imaging, the 
crammed vascular image of  Sa-SCA resembles 
those of  other hypervascular solid tumors, including 
neuroendocrine tumors (NET) and metastatic renal cell 
carcinomas (RCC).[5] Magnetic resonance imaging (MRI) 
with T2-weighted images can show high-intensity signal 
related to the lesion, thus suggesting its microcystic 
nature.[6] Nevertheless, the definitive diagnosis of  
Sa-SCA, as for all other types of  SCN, remains 
challenging because EUS-FNA cytology usually 
results in inconclusive hypocellular or acellular, bloody 
samples.[7-10]
Several years ago, a study by Gerke et al.[11] reported 
a case of  Sa-SCA preoperatively diagnosed by 
EUS-fine-needle biopsy (EUS-FNB) using a Tru-Cut 
needle (Quick-Core needle, Cook Endoscopy, 
Winston-Salem, NC). EUS-FNB increases the yield of  
small tissue fragments, which are useful for ancillary 
stains that could help make a differential diagnosis 
among clear cell neoplasias (SCN, NET, RCC).[12-14] 
Unfortunately, the tru-cut needle was not further 
employed because of  its large bore and difficult 
maneuverability. To the best of  our knowledge, all other 
reported Sa-SCA cases have resulted in the decision to 
proceed with surgical resection for the suspicion of  a 
1(7RU DPDOLJQDQF\ DQG WKH GHÀQLWLYH GLDJQRVLVZDV
always achieved on surgical specimens.[7]
Recently, a novel EUS core biopsy fork-tip needle 
(SharkCore™, Medtronic Corp., Boston, MA, USA) 
has become available in standard calibers. It is 
characterized by two penetrating sharp tips of  varying 
lengths separated by four cutting surfaces and has 
been demonstrated to achieve a high percentage of  
histological specimens.[15]
The aim of  this study was to describe the possibility 
to obtain a preoperative diagnosis of  Sa-SCA by 
using the SharkCore™ needle. Moreover, features of  
preoperative imaging workup and histopathological/
LPPXQRKLVWRFKHPLVWU\ÀQGLQJVZHUHKLJKOLJKWHG
0$7(5,$/6$1'0(7+2'6
Ethics and study population
3DWLHQWVZHUH LGHQWLÀHG IURP D SURVSHFWLYHO\ FROOHFWHG
EUS-procedure database and from the electronic 
pathology archive at the pancreatic care center in 
Verona, Italy.
Data from consecutive adult patients who were referred 
for EUS-FNB of  a solid pancreatic lesion between January 
2016 and January 2018 and were histologically diagnosed 
as having SCN (both preoperatively and/or after resection) 
were retrieved. To exclude cystic lesions, an expert 
radiologist and two endosonographers revaluated computed 
tomography (CT), MRI and EUS images.
The study protocol was approved by the Medical Ethics 
Committee (code 1718CESC).
EUS-f ine-needle biopsy procedures and specimen 
handling
All patients gave informed consent prior to EUS-FNB. 
EUS procedures were performed with patients 
under deep sedation, using a conventional linear 
echoendoscope (EG-3870UTK, Pentax Europe GmbH, 
Hamburg, Germany). Preliminary EUS evaluation 
included lesion echogenicity, location, size, loco-regional 
lymph nodes and vascular pattern after injection 
of  ultrasound contrast media (Sonovue, Bracco, 
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Milan, Italy). A SharkCore™ needle was used with the 
slow-pull technique and whenever possible, the fanning 
technique[16] in all cases. The number of  passes was 
established by the endosonographer according to the 
macroscopic on-site evaluation of  the sample. On-site 
evaluation was not available in any case.
The acquired material underwent standard histologic 
KDQGOLQJ ,WZDVÀ[HG LQ D  IRUPDOGHK\GH VROXWLRQ
embedded in paraffin, sectioned at 3-Pm, and then 
stained with hematoxylin and eosin (H and E). A panel 
of  immunohistochemical markers composed of  
CK8–18 (1:100, Novocastra, Leica Biosystems, UK), 
CK 7 (1:100, Novocastra, Leica Biosystems, UK), 
D-inhibin (1:50, Dako, Denmark), synaptophysin (1:100, 
Novocastra, Leica Biosystems, UK), chromogranin 
A (1:2500, Dako, Denmark), GLUT1 (1:100, 
Thermo Scientific, CA, USA), MUC6 (1:200, Santa 
Cruz Biotechnology, INC, USA) were used, and 
histochemical assays with periodic acid-Schiff  (PAS) and 
PAS with diastase digestion (dPAS) were used. After 
antigen retrieval, immunostaining was performed in an 
autostainer (Bond Max, Leica Biosystems, UK).
Data collected
Collected data were as follows: (1) demographics 
(age, gender); (2) clinical symptoms; (3) preprocedural 
contrast-enhanced cross-sectional imaging (MRI, CT) 
and nuclear medicine examinations (68Ga-somatostatin 
receptor positron emission tomography [68Ga-PET] 
and 18ÁXRURGHR[\JOXFRVH3(7 >)'*3(7@ IHDWXUHV
(4) EUS features (size, location, and margins) and 
EUS-FNB procedure data (needle caliber, number 
of  passes); and (5) procedure-related adverse events 
including intraprocedural retroperitoneal or intraparietal 
bleeding, clinically relevant bleeding (hematemesis, 
melena, or drop >2 g/dl of  hemoglobin compared 
with preprocedural value), perforation and acute 
pancreatitis (abdominal pain associated with an increase 
of  serum pancreatic enzymes over three times the upper 
limit of  normal and/or pancreatitis at imaging); and (6) 
KLVWRORJLFDOÀQGLQJV DQG LPPXQRKLVWRFKHPLFDO IHDWXUHV
RESULTS
Clinical and imaging features
Among nine identified patients, two were excluded 
because of  microcystic appearance at EUS. Therefore, 
seven patients were evaluated (5 females/2 males, mean 
age of  62.5 years, the range of  40–73 years) [Table 1]. 
All lesions were diagnosed preoperatively by EUS-FNB. T
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Pancreatic lesions were all incidentally detected during 
abdominal CT or MRI performed to investigate 
not-specific abdominal pain [Figure 1]. Lesions 
were located in the pancreatic head, neck, and body 
in 2, 2, and 4 cases, respectively. The mean size 
was 19.8 mm (range 7–39 mm). A hypervascular 
pattern was described in all patients, as well as slight 
hyperintense signal on T2-weighted MRI images. 
No upstream dilatation of  the pancreatic duct was 
observed. 68Ga-PET and FDG-PET were performed 
LQ ÀYH SDWLHQWV UHYHDOLQJ QR XSWDNH RI  HLWKHU WUDFHU
A previous standard EUS-FNA was performed in 3 
out of  7 cases, and these smears were bloody and 
acellular.
EUS showed a pure solid appearance and a “crammed 
laminated” aspect in 5 and 2 cases, respectively 
[Figure 2]. Margins were smooth in 5 cases and 
slightly polycyclic/irregular in 2 cases. EUS-FNB 
was performed using a 22- and a 25-G needle in 5 
and in 2 cases, respectively. Three to seven passes 
(median 4) were performed. All specimens were 
considered adequate for the diagnosis. In three patients 
(42.8%), self-limiting retroperitoneal bleeding was 
detected after EUS-FNB without the necessity for a 
prolonged hospital stay. No perforation, pancreatitis, or 
clinically relevant bleeding was observed.
Histologic, histochemical, and immunohistochemical 
analysis
The criteria adopted to ascertain the diagnosis of  SCA 
were according to Reid et al.[2] Histologically, core tissue 
microfragments, composed of  tight back-to-back tubules 
with small, minimal lumina bordered by cuboidal cells 
with eosinophilic or optical empty, clear cytoplasm and 
hyperchromatic, round nuclei were detected against a 
variably bloody background [Figure 3a and b]. Slender 
strands of  connective tissue were intermingled with 
the cellular component of  the core tissues [Figure 3c]. 
Occasionally, solid areas of  detached cells were visible 
within clots. The length of  the fragments was highly 
variable from case to case. The diagnostic morphology 
was adequately evaluable in 5 of  the 7 cases, in which 
biopsy lengths were 600–700 Pm. In the 2 remaining 
cases, the EUS-FNB sample was highly bloody with 
tissue fragments <550 Pm but with preserved areas 
that were suspicious for SCA [Figure 3d]. Histochemical 
positivity for PAS and dPAS was observed in all the 
cases (7/7) [Figure 3e and f]. Immunohistochemical 
positivity of  the clear cells in the tissue fragments 
for D-inhibin (7/7 cases), GLUT1 (6/6 cases), 
and MUC6 (5/5 cases) favored the diagnosis of  
SCA [Figure 4a-c]. All cases were negative for the 
neuroendocrine marker synaptophysin and in 2 cases, 
for chromogranin A as well [Figure 4d and Table 2].
Figure 1. Typical appearance of solid-appearing serous adenoma. The 
arterial phase on magnetic resonance imaging shows a hypervascular 
lesion in the body of the pancreas (a, arrows); in the T1-weighted 
VHTXHQFHLWDSSHDUVDVDK\SRGHQVHVROLGOHVLRQEDQGDW7ZHLJKWHG
images it is slightly hyperdense (c); on EUS, a solid hypoechoic lesion 
is documented (d) with several vascular signals on power-Doppler (e); 
DÀQHQHHGOHELRSV\ZDVWKHQSHUIRUPHGI
dc
b
f
a
e
Figure 2. Two cases of pseudo solid-appearing serous cystic adenomas 
with a “crammed laminated”SDWWHUQDW(86XSSHUTXDGUDQWSDQHOV
DDQGE7ZRH[DPSOHVRIVHURXVF\VWLFDGHQRPDVZLWKSXUHVROLG
aspect indistinguishable from other solid pancreatic neoplasms (lower 
TXDGUDQWSDQHOVFDQGG
dc
ba
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Follow-up
Based on the EUS-FNB results, no patients underwent 
surgical resection. During a mean follow-up of  
20.5 months (range of  12–30), no variation in the 
pancreatic lesion from MRI or symptom onset were 
observed.
DISCUSSION
The preoperative diagnosis of  SCNs of  the pancreas 
is usually the result of  a multidisciplinary discussion of  
clinical, radiological, echoendoscopic, and cytological 
data.[1-4] For pathologists, the diagnosis of  SCNs of  the 
pancreas in a presurgical setting is challenging because 
the cytology suffers from low diagnostic accuracy due 
to the scant cellularity of  the samples,[7,9,17-19] and no 
histological material is routinely recruited from these 
lesions.
2QHRI  WKHPRVW LPSRUWDQW UHFHQW DGYDQFHV LQ WKHÀHOG
of  EUS-guided tissue acquisition is the development of  
so-called “forward-acquiring” needles that obtain tissue 
cores during penetration into the lesion. In particular, 
two types are currently available: The SharkCore™ and 
WKH$FTXLUH %RVWRQ 6FLHQWLÀF&RUS0DUOERURXJK
0$%RWK DUH FKDUDFWHUL]HGE\ DPRGLÀHG WLS IRUNWLS
or Franseen-tip) with several penetrating points and 
cutting surfaces. While pushing these needles into the 
lesion, the shearing tip captures the tissue, keeping 
it intact. Recent studies have demonstrated that is 
possible to achieve true histological samples in >90% 
of  cases.[15]
The current study shows that the preoperative 
histological diagnosis of  SCNs, solid-appearing on 
imaging, is possible. A presurgical histological diagnosis 
Table 2. Immunohistochemical and histochemical results
Case Ş,QKLELQ GLUT1 MUC6 SYN CgA CK8-18 CK7 PAS dPAS
1 + NA + î NA + + + +
2 + + + î î + + + +
3 + + + î NA + NA + +
4 + + NA î NA + NA + +
5 + + NA î NA + NA + +
6 + + + î NA + + + +
7 + + + î î + + + +
6<16\QDSWRSK\VLQ&J$&KURPRJUDQLQ$1$1RWDYDLODEOH3$63HULRGLFDFLG²6FKLɛG3$63HULRGLFDFLG²6FKLɛZLWKGLDVWDVHGLJHVWLRQSRVLWLYLW\QHJDWLYLW\
Figure 4. Immunohistochemical staining in serous cells lining 
tubular structures: D,QKLELQ SRVLWLYH D08&SRVLWLYH E
GLUT1-positive (c), and synaptophysin-negative (d)
dc
ba
Figure 3. Serous adenoma in needle biopsy. Core needle biopsy of 
a highly cellular epithelial lesion with a predominantly compact 
architecture (a). At higher magnification, back-to-back tubular 
structures bordered by cells with serous morphology (b). Slender 
VWUDQGV RI ÀEURXV VWURPD DUH LQWHUPLQJOHGZLWK FHOOXODU DUHDV RI
the serous adenoma (c). Serous morphology is preserved in tissue 
fragments with sub-optimal length (d). The glycogen content in serous 
cells is highlighted by the positive reaction with periodic acid–schiff 
(e) and periodic acid–schiff after diastase digestion (f)
dc
b
f
a
e
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was obtained in 7 patients underwent EUS-FNB, since 
we routinely use the SharkCore™ needle. In all cases, 
the sampling needle retrieved histological fragments. 
They were composed of  small acini with minimal 
glandular spaces, bordered by polygonal cells with 
pale or eosinophilic cytoplasm, adjacent to strands of  
connective tissue [Figure 3a-c]. The clear cell cytology 
of  the epithelium, that is a histological hallmark 
of  SCNs independently of  macroscopic variants 
(microcystic, macrocystic, solid),[2] was well preserved 
even in very small tissue fragments [Figure 3d]. In our 
Sa-SCA series, 3 patients had undergone a previous 
EUS-FNA that had been attempted with a standard 
needle and had resulted in inconclusive diagnoses 
[Table 1]. The reason EUS-FNA usually does not 
retrieve material useful for the diagnosis can be 
explained by the histological structure of  Sa-SCA. 
Indeed, lancet needles, while penetrating into the 
crammed vascularized lesion, rupture the sub-epithelial 
capillaries resulting in bloody and inadequate specimens. 
By contrast, we suppose that the forward-acquiring 
FNB needles, with their several sharp points and 
multifaceted bevels, accomplish coring of  the neoplasm, 
reducing the rupture of  SCA tissue. Therefore, small 
fragments of  well-preserved tumor remain trapped in 
the needle, thereby enabling the pathologist to identify 
the SCA histology architecture.
SCNs with solid or compact structure with 
hypervascularity on imaging evoke the suspicious of  
neoplasia other than SCA and a misdiagnosis could 
lead to an unnecessary surgery.[2,20] Our series outlined 
several preoperative imaging features, raising the index 
of  suspicion of  Sa-SCA [Table 1]. These lesions appear 
hypervascular at imaging, with a hyperdense signal on 
T2-weighted MRI, without uptake in either 68Ga-or 
FDG-PET. Nevertheless, even though MRI T2-weighted 
images of  Sa-SCA tend to maintain high intensity 
ORQJHU WKDQGR1(7V LW LV RIWHQGLIÀFXOW WRGLVWLQJXLVK
them from other solid pancreatic tumors, including 
NETs, acinar cell carcinomas, solid pseudopapillary 
tumors, and metastases from highly vascular carcinomas. 
For these reasons, histological diagnosis is desirable to 
decrease the hazards of  unnecessary resections.
Morphologically, primary clear cell NET and RCC 
metastatic to the pancreas are the major mimickers 
of  Sa-SCA. Immunohistochemistry is mandatory to 
generate a differential diagnosis among the malignant 
and nonmalignant tumors with clear cell features in 
the pancreas. Neuron-specific enolase, D-inhibin and 
mucin-related glycoprotein MUC1 and MUC6 positivity 
have been recognized as unique immunoprofiles 
for SCNs to differentiate it from other pancreatic 
tumors.[11,12] Furthermore, markers of  clear cell 
tumorigenesis (GLUT-1, HIF1-D, and CAIX)[21,22] and 
calponin[23] have been detected in SCNs, as well.
In the EUS-FNB series of  the current study, 
the diagnosis of  SCA was supported by 
LPPXQRKLVWRFKHPLVWU\ZLWK D VWDLQLQJSURÀOH FRQVLVWHQW
with the profile described in the literature [Table 2]. 
The material retrieved by the sampling needle was, in 
terms of  quality and quantity [Figure 3], adequate to 
apply a wide panel of  antibodies capable of  assessing 
the serous nature of  the lesions and to exclude the 
suspicion of  other clear cell neoplasias [Figure 4]. 
SCNs are not recognized by a specific antibody, but 
by a distinctive immunohistochemical signature.[11,12,22] 
To increase accuracy, several antibodies need to be 
used. More available neoplastic material increases the 
morphological and immunohistochemical diagnostic 
accuracy.[23] Standard EUS-FNA recruits very few cells 
from SCNs, and cytological diagnosis is challenging. 
To improve sample cellularity, the cell-block has been 
proposed by some authors, with variable results.[18,24,25] 
However, in cell-blocks with abundant cellularity, the 
presence of  contaminating gastrointestinal epithelium 
or neuroendocrine cells derived by benign islets could 
result in misinterpretation.[12] By contrast, in EUS-FNB 
tissue, the correlation between the morphology and the 
topographic distribution of  antibody staining reduces 
the risk of  misdiagnosis.[26] All the Sa-SCAs of  our 
series showed precise immunohistochemical staining 
thanks to the well-preserved morphology of  the 
material [Figure 4]. No artifacts secondary to crushing 
effects of  the sampling needle were observed.
The high rates of  intraprocedural bleeding reported in 
this study deserve to be discussed. In three (42.8%) 
patients, we observed the onset of  retroperitoneal 
hematoma. The combination of  end-cutting tip 
needles and hypervascular lesions can explain such 
high percentage. However, all cases were self-limiting 
and relatively trivial. No patients developed symptoms 
or required prolonged hospitalization or medical 
intervention. Therefore, according to the American 
Society for Gastrointestinal Endoscopy criteria, they 
are not significant enough clinically to be called 
“adverse events.”[27] However, some few procedural 
adjustments could be useful to prevent sequelae. 
According to our experience, we could suggest to 
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reduce the number of  back and forth movements 
during the sampling, thus reducing intralesion trauma. 
Whenever possible, in between the biopsy passes, it 
could be useful to apply a gently pressure with the 
ultrasound transducer over the needle entrance to 
reduce the needle tract bleeding.
This study has several limitations. First, the number of  
patients was limited; nevertheless, the rarity of  Sa-SCA 
PDNHV LW GLIÀFXOW WR JDWKHU D ODUJHUSRSXODWLRQ 6HFRQG
none of  our patients underwent surgical resection to 
FRQÀUP WKH GLDJQRVLV KRZHYHU SUHRSHUDWLYH GLDJQRVLV
aims to avoid unnecessary surgery. Third, we cannot 
draw any conclusion regarding EUS-FNB diagnostic 
accuracy in this setting of  patients. Fourth, selection 
bias of  cases might exist since only Sa-SCAs were 
LQFOXGHG 6ROLG DSSHDUDQFH FRXOG UHÁHFWGHQVH FHOOXODULW\
WKDWPLJKW IDFLOLWDWH WR REWDLQ VXIÀFLHQW VSHFLPHQ WKLV
condition could not be present in others SCA variants. 
Finally, we have not a structured control group to 
compare with standard cytology, even if  three of  our 
patients had a previous EUS-FNA. Moreover, published 
literature is clear in decreeing the failure of  cytology in 
this setting of  patients.
CONCLUSIONS
Sa-SCA is a rare entity that is often misdiagnosed 
and treated with unnecessary surgical resection. 
Typical preoperative workup shows a hypervascular 
lesion with a sl ightly hyperintense signal on 
T2-weighted MRI, without uptake on nuclear medicine 
examinations. The use of  a forward-acquiring 
needle can help achieve definitive histological 
diagnosis. The well-preserved histology of  the 
needle biopsy guarantees the quality standards for 
immunohistochemical staining.
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